Woods G L
University of Texas Medical Branch, Galveston, TX 77555-0740, USA.
Clin Infect Dis. 2000 Nov;31(5):1209-15. doi: 10.1086/317441. Epub 2000 Nov 6.
Mycobacterial susceptibility testing is important for the management of patients with tuberculosis and those with disease caused by certain nontuberculous mycobacteria. To help standardize methods used in the clinical microbiology laboratory for testing susceptibility of mycobacteria, the National Committee for Clinical Laboratory Standards (NCCLS) recently updated NCCLS document M24-T (published in 1995), which is the tentative standard for antimycobacterial susceptibility testing of Mycobacterium tuberculosis. The second edition of the NCCLS tentative standard (document M24-T2) differs considerably from the initial document. It contains revised guidelines for the testing of M. tuberculosis complex and newly proposed guidelines for the testing of some nontuberculous mycobacteria, including the rapidly growing mycobacteria (Mycobacterium fortuitum group, Mycobacterium chelonae, and Mycobacterium abscessus), Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium marinum, as well as Nocardia species and other aerobic actinomycetes. The recommendations for mycobacterial susceptibility testing that are outlined in NCCLS document M24-T2 are reviewed.
分枝杆菌药敏试验对于结核病患者以及某些非结核分枝杆菌所致疾病患者的治疗管理至关重要。为帮助临床微生物实验室规范用于检测分枝杆菌药敏性的方法,美国国家临床实验室标准委员会(NCCLS)最近更新了NCCLS文件M24-T(1995年发布),该文件是结核分枝杆菌抗分枝杆菌药敏试验的暂行标准。NCCLS暂行标准第二版(文件M24-T2)与初始文件有很大不同。它包含了结核分枝杆菌复合群检测的修订指南以及一些非结核分枝杆菌检测的新提议指南,包括快速生长分枝杆菌(偶然分枝杆菌群、龟分枝杆菌和脓肿分枝杆菌)、鸟分枝杆菌复合群、堪萨斯分枝杆菌、海分枝杆菌,以及诺卡菌属和其他需氧放线菌。本文对NCCLS文件M24-T2中概述的分枝杆菌药敏试验建议进行了综述。